Clinical Scenario: A 61-Year-Old Woman with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
Michael Rosenzweig, MD, MS, presents the clinical scenario of a 61-year-old woman with transplant-eligible newly diagnosed multiple myeloma to the panel for discussion.
Now Viewing
EP: 1.Clinical Scenario: A 61-Year-Old Woman with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
EP: 2.Induction Treatment Regimens for Patients With Transplant-Eligible NDMM
EP: 3.Treatment Strategies for Patients With High-Risk NDMM
EP: 4.Clinical Scenario: A 68-Year-Old Man With Transplant-Ineligible NDMM
EP: 5.Selecting Between DRd and VRd Combination Regimens for Patients With Transplant-Ineligible NDMM
EP: 6.Factors for Consideration When Treating Frail Patients With Transplant-Ineligible NDMM
EP: 7.Bone Disease Prophylaxis in Patients With Transplant-Eligible NDMM
EP: 8.Clinical Scenario: A 61-Year-Old Woman With Relapsed/Refractory Multiple Myeloma (R/R MM)
EP: 9.Choosing Between Bispecific or CAR T-Cell Therapy for Patients With Multiple Myeloma
EP: 10.Toxicity Management in Patients With Multiple Myeloma
EP: 11.Expert Perspectives on Quadruplet Therapy Regimens for Patients With Multiple Myeloma
EP: 12.Looking Ahead in the Multiple Myeloma Treatment Landscape
EP: 13.CAR T-Cell Therapy Vs Bispecific Antibodies As Multiple Myeloma Treatment
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
